drugset / Trial / NCT00531466

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury

NCT00531466

Phase 2 Terminated 120 enrolled Avigen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity following a spinal cord injury. This study has three purposes: 1. To determine whether AV650 is safe for patients with spinal cord injury; 2. To assess what the body does with AV650 once it is ingested; and, 3. To gather some early evidence as to whether AV650 is effective in treating spasticity in patients with spinal cord injury.

Timeline

Start
2007-09
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tolperisone Small molecule Oral

Indications

No indication recorded.